It is very uncertain whether VCT changes syphilis prevalence among FSWs at 6‐month compared with standard care of STI (very low certainty).
It is very uncertain whether VCT changes gonorrhoea prevalence among FSWs at 6‐month compared with standard care of STI (very low certainty).
It is very uncertain whether VCT changes chlamydia prevalence among FSWs at 6‐month compared with standard care of STI (very low certainty).
It is very uncertain whether VCT changes trichomonas prevalence among FSWs at 6‐month compared with standard care of STI (very low certainty).
VCT may leads to lower genital warts prevalence among FSWs at 6‐month compared with standard care of STI (low certainty).
It is very uncertain whether VCT changes consistent condom use by FSWs with clients at 6‐month compared with standard care of STI (very low certainty).
It is very uncertain whether VCT changes HIV/STI knowledge among FSWs at 6‐month compared with standard care of STI (very low certainty).
Social cognitive theory showed no clear difference in gonorrhoea incidence among FSWs at 6‐month compared with standard counseling (moderate certainty).
Social cognitive theory probably leads to lower any STIs incidence among FSWs at 6‐month compared with standard counseling (moderate certainty).
It is very uncertain whether social cognitive theory changes consistent condom use by FSWs at 6‐month compared with standard counseling (very low certainty).
Social cognitive theory showed no clear difference in drug use among FSWs at 6‐month compared with standard counseling (low certainty).
Social cognitive theory showed no clear difference in alcohol use among FSWs at 6‐month compared with standard counseling (low certainty).
Social cognitive theory for promotion of condom use showed no clear difference in consistent condom use by FSWs with clients at 6‐month compared with no intervention (moderate certainty).
The intervention may leads to higher full desensitization to milk (low certainty).
naltrexone showed no clear difference in retention and abstinence, all patients compared with placebo or no pharmacological treatments; GRADE not reported.
naltrexone showed no clear difference in abstinence at compared with placebo or no pharmacological treatments; GRADE not reported.
naltrexone showed no clear difference in side effects compared with placebo or no pharmacological treatments; GRADE not reported.
Summary of findings: intranasal steroids showed no clear difference in hearing loss (Audiometry failing) [9 months]2 compared with control (moderate certainty).
Summary of findings: intranasal steroids showed no clear difference in OME resolution at short‐term compared with control (moderate certainty).